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Slumen we placed a second, shorter stent in the upper part of the ﬁrst stent. The
Edwards Sapien XT valve mounted on the Novaﬂex delivery system was then
deployed In the dual caval valve approach we implanted a second valve into the vena
cava superior (SVC) as described.
Results: From August 2nd, 2012 to now we treated 6 pts (2 f, 4 m; 5 ICV single, 1
IVC and SVC dual valve) with a FU up to 11 mo. Safety: Periprocedural mortality:
0%; technical success: 100%; VARC 30-day safety endpoint: 0%, valve dysfunction:
0%. Clinical results: 5/6 pts improved by at least 1 NYHA class, in 5/6 pts signs of
right heart congestion decreased, in 2/2 pts with cardiorenal syndromes and terminal
failure renal function improved allowing discontinuation of dialysis. In 6/6 pts hepatic
veins diameters decreased (-34%). Right heart parameters: In msCT measurements
volumes of the anatomical RV decreased (-14,8%), surprisingly, also volumes of the
anatomical RA decreased (-13%). In echo measurements, TAPSE increased from 14,5
to 18,6 cm.
Conclusions: Percutaneous single or dual caval valve implantation with the Edwards
Sapien XT for severe TR is feasible and safe.With all due care at this early stage, this
approach appears to be a new promising interventional tool to improve right heart
hemodynamics and to ameliorate symptoms of right heart failure in advanced stages of
heart failure.
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Background: Transcatheter aortic-valve implantation (TAVI) has rapidly evolved as
an effective treatment alternative for aortic-valve disease. The currently utilized bio-
prostheses are prone functional degeneration. Autologous, stem cell based, tissue-
engineered heart-valves (TEHV) with self-repair capacity have been repeatedly
proposed to overcome these limitations. We summarize our initial experience on
marrow stromal cell based TAVI in an adult sheep model.
Methods: Tri-leaﬂet TEHV generated from synthetic-scaffolds were integrated into
self-expanding Nitinol stents, seeded with autologous marrow-stromal cells. There-
after, in a series of animal experiments, TEHV were transapically delivered into the
descending aorta (n¼3) and the orthotopic aortic-valve position of adult sheep (n¼16)
using different delivery systems including a generic system and the anatomically-
orienting JenaValve transapical TAVI System (JenaValve, Munich/Germany). Follow
up was up to two weeks. Positioning and functionality were assessed by angiography
and echo before the TEHV underwent post-mortem gross examination and histology.
CT scan was used to assess stent positioning.
Results: Transcatheter implantation of TEHV into the descending aorta (n¼3) and
into the orthotopic aortic-valve position (n¼16) was successful in all animals. Fluo-
roscopy and echo conﬁrmed sufﬁcient positioning at the intended delivery site. All
TEHV tolerated the loading-pressure of the systemic-circulation and no acute ruptures
or tears occurred. Animals displayed intact and mobile leaﬂets with an adequate
functionality (mean trans-valvular gradient <10mmHg in all animals). Importantly,
TEHV orthotopically implanted (n¼16) entirely excluded the native aortic leaﬂets and
did not compromise the coronary arteries. Histology was indicative for an early
cellular-remodelling.
Conclusions: We demonstrate transcatheter based TEHV implantation into the aorta
within a one-step intervention. Our data indicate the feasibility to combine the concept
of TEHV and transcatheter delivery representing a key step towards clinical trans-
lation. Long-term functionality proven, a cell based TEHV approach may represent
a next generation heart-valve therapy concept.
TCT-131
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Background: Percutaneous mitral valve repair requires a close understanding of both
ﬂuoroscopy and periprocedural imaging. Real time 3D transesophageal echocardi-
ography is often used for guidance. We report the use of 3D-echocardiography-
ﬂuoroscopy fusion for mitral valve repair.
Methods: Patients presenting to our center for mitral valve repair had their procedure
performed using an echocardiographic-ﬂuoroscopic overlay system. The EchoNavi-
gator (Philips, Inc) system requires transesophageal echocardiography, which is
registered to ﬂuoroscopy based on probe angle and position. Relevant structures can
be marked on echocardiography and tracked with ﬂuoroscopy. Procedural charac-
teristics of these patients were collected.
Results: Nine patients at our center underwent percutaneous mitral valve repair with
MitraClip (Abbott Vascular, Santa Clara, CA) using a novel 3D-echocardiographic-
ﬂuoroscopic overlay technology (EchoNavigator, Philips Inc.). The EchoNavigator
system was useful for transseptal puncture, understanding mitral valve anatomy,
sheath exchange, clip advancement, and post-deployment visualization.B42 JACC Vol 62/18/Suppl B j October 27–November 1, 2013 j TCT Abstracts/ORAL/25 YConclusions: The use of EchoNavigator echo-ﬂuoroscopy overlay system is feasible
and useful in MitraClip intervention.TCT-132
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Background: We evaluated an alternative method to treat post PTA dissection using
a novel device, The Tack-IT Endovascular System, by Intact Vascular, Wayne, PA,
indicated for tissue apposition to optimize angioplasty results in peripheral arteries.
The Tack is a circumferential, self-expanding Nitinol device 6mm in length. The Tack
is designed to provide focal treatment only where needed. The Tack accommodates
arterial diameters between 2.5 - 5.5mm and has low outward force onto the arterial
wall. Up to 8 Tacks can be used to treat lesions up to 100mm in length.
Methods: One hundred thirty eight subjects were enrolled in the Tack Optimized
Balloon Angioplasty (TOBA) study. The lesion length was <100mm. The primary
endpoints were Safety and Device Technical Success at 30 days. Safety included
major device-related adverse event(s) including device embolization, emergency
surgical revascularization, index limb amputation (above the ankle) or clinically-
driven TLR at 30 days. Device Technical Success was the ability of the Tack to
resolve post-PTA dissection demonstrated that the artery at the Tack(s) location
remained patent at the end of the procedure (<30 % residual stenosis). Subjects were
followed 1, 6 and 12 months.
Results: FULL STUDY RESULTS WILL BE AVAILABLE BY TCT. Ninety one of
the 138 subjects are enrolled. The mean age was 70 with 62% males. The co-
morbidities included 65% with diabetes, 62% smokers, 73% hypertension and 64%
elevated cholesterol. Eighty four (84) subjects had a sub-optimal PTA, 5 optimal PTA
and 2 did not meet the I/E criteria. The mean lesion length was 47.5mm and RVD
5.40mm. At 30 days (primary endpoint) there were no major device-related adverse
events, emergency surgical revascularizations, no index limb amputations. One (1)
clinically-driven TLR (1.2%) reported. One hundred percent (100%) technical success
was achieved in all the treated lesions and all (292) Tacks were successfully placed.
Conclusions: The Tack is designed to create tissue apposition with minimal amount
of metal and low outward force to allow natural arterial ﬂexibility and low neointimal
response. Long term clinical evidence will conﬁrm the clinical beneﬁts of this novel
technology.
TCT-133
THEMULTILAYER FLOWMODULATOR STENT FOR THE TREATMENT
OF PERIPHERAL AND VISCERAL ANEURYSMS.
Michel C. Henry1, Amira Benjelloun2, Isabelle P. henry3, Antonios Polydorou4
1Cabinet de cardiologie, nancy, France, 2Clinique Coeur et Vaisseaux, RABAT,
Morocco, 3Polyclinique Bois Bernard, BOIS BERNARD, France, 4Panteleimon
General Hospital, Athens, Greece
Background: Arterial aneurysms (An) are traditionally treated surgically, but more
and more by interventional procedures with a high technical success rate, but some
problems are not solved like protection of aneurysm rupture, endoleaks, stent
thrombosis, collateral branch thrombosis. We used a new concept of stent, the
Multilayer Flow Modulator (MFM*) to treat An. and try to avoid some drawbacks
encountered with endografts.
Methods: This MFM* is a 3 Dimensional braided tube made of several inter-
connected layers without any covering. Our earliest in vitro (theorical simulation),
computerized Fluid dynamics, Molecular Modelization and in vivo tests demonstrated
that this MFM* reduces the velocity in the aneurismal sac up to 90% by modifying theears of Interventional Innovation: Novel Therapies and the “Emerging” Device Concepts for 2013
www.jacctctabstracts2013.com MONDAY, OCTOBER 28, 2013, 8:00 AM–6:35 PMhemodynamic conditions. A saccular aneurysm without collateral branch will
thrombose quickly. If a collateral branch is present the ﬂow is directed towards this
branch leading to shrinkage of the aneurysm. Animal experiments show excellent
results. Moreover, as demonstrated in animal and human studies this MFM* preserves
the collateral branches allowing the possibility to cover any artery without compro-
mising the ﬂow (renal, digestive arteries, supra aortic vessels.)
Results: 40 peripheral An. (iliac:23, femoral:1, popliteal:5, renal:8, mesenteric:1,
carotid: 1, Subclavian : 1) were treated with the MFM* (male:31, mean age 62+/-8 y)
(52 stents Ø 5 to 14 mm; length 40 to 120 mm) were implanted to treat these aneu-
rysms, by femoral approach (39 cases), brachial approach (1 case), Technical success
in all patients. No complications. All An. thrombosed with diameter reduction in some
pts. The thrombosis could take several weeks depending on the importance of
collateral branches. 6 month to 36 month follow up will be presented and we will
discuss the time needed to achieve exclusion of the An. All the side branches remained
patent.
Conclusions: A new concept of stent, the MFM* (without any covering) is developed
to treat An. It opens a new approach to treat peripheral An. avoiding most of the
complications encountered with current endovascular techniques. The results obtained
seem promising. A larger study is ongoing.
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Background: Central sleep apnea (CSA), usually presenting as Hunter-Cheyne-
Stokes Breathing, occurs in approximately 35% of patients with heart failure. Current
treatment options for CSA have been limited and focus on mask based therapies and
therefore are highly dependent on tolerability and adherence. A novel therapy utilizing
phrenic nerve stimulation was developed using the remede System, a transvenous,
fully implantable system that is intended to restore a normal breathing pattern
throughout the night. This is the ﬁrst presentation of the study cohort with reduced
ejection fraction (EF) to evaluate of the remede System through 3 and 6 months.
Methods: Subjects received a remede System consisting of a respistimTM trans-
venous stimulation lead (in either the left pericardiophrenic or right brachiocephalic
vein) and a remede pulse generator which was placed in the pectoral area and secured
in a normal fashion. Thirty-ﬁve subjects with predominantly central sleep apnea were
enrolled. Subjects had an ejection fraction < 40% Subjects (age 659 years) and were
able to be evaluated at 3 and 6 months of therapy. 62% percent of subjects had
a concomitant cardiac device and 86% of subjects had chronic heart failure symptoms.
Standard PSG criteria were used for classiﬁcation of respiratory events and arousals.
Results: Both 3 and 6 month data demonstrate signiﬁcant improvements in apnea-
hypopnea index (AHI), central apnea index, oxygen desaturation index of 4%, arousal
index, REM sleep and sleep efﬁciency. In addition, there were signiﬁcant improve-
ments in quality of life at 6 months seen both in MLWHF (p¼0.0012) and NYHA
Classiﬁcation (p<0.0001).Changes in Respiratory and Symptoms with 6 months of remede System
Therapy
Parameter
Baseline
Mean +/-
Std Dev
3 Months
Mean +/-
Std Dev
6 Months
Mean +/- Std
Dev
Paired T-test
(Baseline to 6
Months
Apnea Hypopnea Index
(n/hr)
5115 2513 2413 <0.0001
Central Apnea Index
(n/hr)
3015 59 47 <0.0001
Oxygen Desaturation
Index 4% (n/hr)
4719 2413 2413 <0.0001
Arousal Index (n/hour) 3917 2611 2713 0.0002
Sleep Efﬁciency (%) 6818 7616 8013 0.0002
REM sleep (%) 106 168 186 <0.0001
MLWHFQ 3323 NA 2421 0.0012
Epworth Sleepiness
Scale
7.43.5 NA 4.72.9 <0.0001
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SConclusions: Treatment of CSA with the remede System signiﬁcantly improves
both respiratory and sleep parameters as well as symptoms of heart failure, in patients
with reduced EF. These favorable changes in pathophysiological consequences of
sleep apnea may lead to improvements in outcomes in patients with heart failure.JACC Vol 62/18/Suppl B j October 27–November 1, 2013 j TCT Abstracts/ORAL/25 Years oTCT-135
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Background: To describe the technique and proof the concept of a complete trans-
apical deployment of a single sidebranch arch endograft in a porcine model.
Methods: Eight domestic pigs were operated with antegrade transapical delivery of
a single-sidebranch arch endograft including a mating stentgraft to the innominate
artery. Technical feasibility, operating time, radiation parameters and hemody-
namic changes were studied according to standardized protocol during baseline
(T0), after establishing of the transapical access and through-and-through wire
(T1) and after stent-graft deployment (T2). Myocardial and cerebral perfusion
were assessed by ﬂuorescent-microspheres (FM) and transit-time-ﬂow measure-
ment (TTFM).
Results: Transapical access, introduction and deployment of the endograft, side-
branch catheterization and deployment of the mating stent-graft were feasible in 6 of
the 8 animals with unimpeded perfusion of the innominate artery. One animal was lost
during transapical access, one during sire-branch catheterization. The mean operating
and ﬂuoroscopy times were 15747min and 15.93.2min. During introduction and
deployment of the stent-graft transient aortic valve insufﬁciency occurred in all
animals. Hemodynamic stability recovered within ten minutes after retrieval of the
delivery system in all animals. The innominate artery was patent with unchanged
TTFM-ﬂow measurements throughout the procedure. FM evaluation revealed stable
myocardial and cerebral perfusion.
Conclusions: Antegrade transapical access to the aortic arch for implantation of
a single sidebranch arch endograft is feasible in a porcine model with reversible
impact on hemodynamic measures during deployment. Transapical access allows for
deployment of a complex endograft through a single large bore access-site in a porcine
model. It might be a future treatment option for selective patients.
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Background: Diastolic dysfunction develops in most cardiac conditions, and leads to
elevation of left ventricular ﬁlling pressures and heart failure. We report the initial
experience with a novel device intended to lower left atrial pressure by creating
a small permanent atrial septal shunt. The objective of the study was to evaluate safety
and potential beneﬁts of the Intra Atrial Shunt Device (IASD) System in patients
with symptomatic heart failure with preserved or mildly reduced ejection fraction,
despite appropriate medical management.
Methods: The ﬁrst 6 patients in a prospective multicenter feasibility study were
enrolled under an approved protocol. Key inclusion criteria were: EF > 45%; PCWP
at rest  15 or exercise  25mm Hg; or  1 hospitalization for heart failure within
prior 12 months; or persistent NYHA Class III/IV for at least 3 months.
Results: Mean age, EF, and NYHA Class were 75 Y, 57 %, and III, respectively.
Most patients had multiple comorbidities. The IASD Device was successfully
implanted in each patient using standard interventional techniques and guidance. One
SAE (complete heart block) occurred within 30 days, and resolved (pacemaker). The
SAE was not related to the procedure or device. At 30 days, PCWP was reduced, and
at 30 days clinical symptoms had improved in 5 of 6 patients. Additional follow-up
data will be presented.f Interventional Innovation: Novel Therapies and the “Emerging” Device Concepts for 2013 B43
